Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | CHAT | P28329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768883 | 1.00 | PTGS1 (0.41) | PTGS1FBP1PPARGMAPK14CES2 | |
| SCHEMBL3663676 | 0.92 | FBP1 (0.40) | PTGS1FBP1CHRM5CYP1A2CYP2C9 | |
| SCHEMBL3772088 | 0.92 | FBP1 (0.40) | PTGS1FBP1CHRM5CYP1A2CYP2C9 | |
| SCHEMBL3769833 | 0.90 | MDM2 (0.40) | PTGS1FBP1PPARGCES2CES1 | |
| SCHEMBL3769829 | 0.90 | MDM2 (0.40) | PTGS1FBP1PPARGCES2CES1 | |
| SCHEMBL3776425 | 0.87 | CES2 (0.40) | PTGS1CES2CES1PTGS2MDM2 | |
| SCHEMBL3776421 | 0.87 | CES2 (0.40) | PTGS1CES2CES1PTGS2MDM2 | |
| SCHEMBL3769981 | 0.85 | PTGS1 (0.43) | PTGS1PPARGCES2CES1CYP1A2 | |
| SCHEMBL3769986 | 0.85 | PTGS1 (0.43) | PTGS1PPARGCES2CES1CYP1A2 | |
| SCHEMBL3769281 | 0.84 | CES2 (0.40) | PTGS1CES2CES1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | PTGS1 259/4885FBP1 855/4885PPARG 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.